Vasopressin and Methylprednisolone vs Placebo on Return of Spontaneous Circulation in In-Hospital Cardiac Arrest | Cardiology | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Effect of Vasopressin and Methylprednisolone vs Placebo on Return of Spontaneous Circulation in Patients With In-Hospital Cardiac ArrestA Randomized Clinical Trial

Educational Objective
To learn whether the combination of vasopressin and methylprednisolone administered during in-hospital cardiac arrest improves return of spontaneous circulation.
1 Credit CME
Key Points

Question  Does the combination of vasopressin and methylprednisolone administered during in-hospital cardiac arrest improve return of spontaneous circulation?

Findings  In this randomized trial that included 501 patients with in-hospital cardiac arrest in Denmark, the proportion of patients who achieved return of spontaneous circulation was 42% in the vasopressin and methylprednisolone group and 33% in the placebo group, a difference that was statistically significant.

Meaning  Among patients with in-hospital cardiac arrest, administration of vasopressin and methylprednisolone compared with placebo significantly increased the likelihood of return of spontaneous circulation, but it is uncertain whether there is benefit or harm for long-term survival.

Abstract

Importance  Previous trials have suggested that vasopressin and methylprednisolone administered during in-hospital cardiac arrest might improve outcomes.

Objective  To determine whether the combination of vasopressin and methylprednisolone administered during in-hospital cardiac arrest improves return of spontaneous circulation.

Design, Setting, and Participants  Multicenter, randomized, double-blind, placebo-controlled trial conducted at 10 hospitals in Denmark. A total of 512 adult patients with in-hospital cardiac arrest were included between October 15, 2018, and January 21, 2021. The last 90-day follow-up was on April 21, 2021.

Intervention  Patients were randomized to receive a combination of vasopressin and methylprednisolone (n = 245) or placebo (n = 267). The first dose of vasopressin (20 IU) and methylprednisolone (40 mg), or corresponding placebo, was administered after the first dose of epinephrine. Additional doses of vasopressin or corresponding placebo were administered after each additional dose of epinephrine for a maximum of 4 doses.

Main Outcomes and Measures  The primary outcome was return of spontaneous circulation. Secondary outcomes included survival and favorable neurologic outcome at 30 days (Cerebral Performance Category score of 1 or 2).

Results  Among 512 patients who were randomized, 501 met all inclusion and no exclusion criteria and were included in the analysis (mean [SD] age, 71 [13] years; 322 men [64%]). One hundred of 237 patients (42%) in the vasopressin and methylprednisolone group and 86 of 264 patients (33%) in the placebo group achieved return of spontaneous circulation (risk ratio, 1.30 [95% CI, 1.03-1.63]; risk difference, 9.6% [95% CI, 1.1%-18.0%]; P = .03). At 30 days, 23 patients (9.7%) in the intervention group and 31 patients (12%) in the placebo group were alive (risk ratio, 0.83 [95% CI, 0.50-1.37]; risk difference: −2.0% [95% CI, −7.5% to 3.5%]; P = .48). A favorable neurologic outcome was observed in 18 patients (7.6%) in the intervention group and 20 patients (7.6%) in the placebo group at 30 days (risk ratio, 1.00 [95% CI, 0.55-1.83]; risk difference, 0.0% [95% CI, −4.7% to 4.9%]; P > .99). In patients with return of spontaneous circulation, hyperglycemia occurred in 77 (77%) in the intervention group and 63 (73%) in the placebo group. Hypernatremia occurred in 28 (28%) and 27 (31%), in the intervention and placebo groups, respectively.

Conclusions and Relevance  Among patients with in-hospital cardiac arrest, administration of vasopressin and methylprednisolone, compared with placebo, significantly increased the likelihood of return of spontaneous circulation. However, there is uncertainty whether this treatment results in benefit or harm for long-term survival.

Trial Registration  ClinicalTrials.gov Identifier: NCT03640949

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Article Information

Corresponding Author: Lars W. Andersen, MD, MPH, PhD, DMSc, Research Center for Emergency Medicine, Department of Clinical Medicine and Emergency Department, Aarhus University and Aarhus University Hospital, Palle Juul-Jensens Blvd 161, 8200 Aarhus N, Denmark (lwandersen@clin.au.dk).

Accepted for Publication: September 13, 2021.

Published Online: September 29, 2021. doi:10.1001/jama.2021.16628

Author Contributions: Dr Andersen had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Andersen and Granfeldt.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Andersen and Granfeldt.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Andersen and Holmberg.

Obtained funding: Andersen.

Administrative, technical, or material support: All authors.

Conflict of Interest Disclosures: Dr Andersen reported receiving grants from Aarhus University Research Foundation, the Department of Clinical Medicine at Aarhus University, and Independent Research Fund Denmark, and nonfinancial support from Amomed Pharma GmbH, which provided trial drug during the conduct of the study. Dr J. Kjærgaard reported receiving grants from the Novo Nordisk Foundation (NNF17OC0028706) outside the submitted work. Dr Lauridsen reported receiving grants from Independent Research Fund Denmark during the conduct of the study. Dr Kurth reported receiving personal fees from Teva, TotalEnergies, Eli Lilly & Company, and The BMJ outside the submitted work. Dr Granfeldt reported receiving personal fees from Noorik Biopharmaceuticals outside the submitted work. No other disclosures were reported.

Funding/Support: Funding for the trial was provided by Aarhus University Research Foundation; the Department of Clinical Medicine, Aarhus University; the Central Denmark Region; and the Independent Research Fund Denmark. Empressin and corresponding placebo ampoules were provided free of charge by Amomed Pharma GmbH.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Meeting Presentation: Presented via livestream for Critical Care Reviews; September 29, 2021.

Data Sharing Statement: See Supplement 3.

Additional Contributions: We thank the clinical teams that facilitated inclusion of patients at the participating centers as well as the members of the independent data monitoring committee (Christian Fynbo Christiansen, MD, PhD, Aarhus University; Jasmeet Soar, MD, Southmead Hospital; and Hans Friberg, MD, PhD, Skåne University Hospital). We also thank Therese Straarup, MD, PhD, Mette Poulsen, MD, Phillip Caap, MD, all from Viborg Regional Hospital, and Thomas Dissing, MD, PhD, Aarhus University Hospital, for assisting with trial conduct. None of the listed persons were compensated for their work related to this trial.

References
1.
Holmberg  MJ , Ross  CE , Fitzmaurice  GM ,  et al; American Heart Association’s Get With The Guidelines–Resuscitation Investigators.  Annual incidence of adult and pediatric in-hospital cardiac arrest in the United States.   Circ Cardiovasc Qual Outcomes. 2019;12(7):e005580. doi:10.1161/CIRCOUTCOMES.119.005580PubMedGoogle Scholar
2.
Andersen  LW , Holmberg  MJ , Løfgren  B , Kirkegaard  H , Granfeldt  A .  Adult in-hospital cardiac arrest in Denmark.   Resuscitation. 2019;140:31-36. doi:10.1016/j.resuscitation.2019.04.046PubMedGoogle ScholarCrossref
3.
Andersen  LW , Holmberg  MJ , Berg  KM , Donnino  MW , Granfeldt  A .  In-hospital cardiac arrest: a review.   JAMA. 2019;321(12):1200-1210. doi:10.1001/jama.2019.1696PubMedGoogle ScholarCrossref
4.
Perkins  GD , Ji  C , Deakin  CD ,  et al; PARAMEDIC2 Collaborators.  A randomized trial of epinephrine in out-of-hospital cardiac arrest.   N Engl J Med. 2018;379(8):711-721. doi:10.1056/NEJMoa1806842PubMedGoogle ScholarCrossref
5.
Kudenchuk  PJ , Brown  SP , Daya  M ,  et al; Resuscitation Outcomes Consortium Investigators.  Amiodarone, lidocaine, or placebo in out-of-hospital cardiac arrest.   N Engl J Med. 2016;374(18):1711-1722. doi:10.1056/NEJMoa1514204PubMedGoogle ScholarCrossref
6.
Mentzelopoulos  SD , Zakynthinos  SG , Tzoufi  M ,  et al.  Vasopressin, epinephrine, and corticosteroids for in-hospital cardiac arrest.   Arch Intern Med. 2009;169(1):15-24. doi:10.1001/archinternmed.2008.509PubMedGoogle ScholarCrossref
7.
Mentzelopoulos  SD , Malachias  S , Chamos  C ,  et al.  Vasopressin, steroids, and epinephrine and neurologically favorable survival after in-hospital cardiac arrest: a randomized clinical trial.   JAMA. 2013;310(3):270-279. doi:10.1001/jama.2013.7832PubMedGoogle ScholarCrossref
8.
Panchal  AR , Bartos  JA , Cabanas  JG ,  et al.  Part 3: Adult Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.   Circulation. 2020;142(16_suppl_2):S366-S468.Google Scholar
9.
Soar  J , Böttiger  BW , Carli  P ,  et al.  European Resuscitation Council Guidelines 2021: adult advanced life support.   Resuscitation. 2021;161:115-151. doi:10.1016/j.resuscitation.2021.02.010PubMedGoogle ScholarCrossref
10.
Andersen  L , Sindberg  B , Holmberg  M ,  et al  Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest: Protocol for a Randomized, Double-Blind, Placebo-Controlled Trial. Resuscitation Plus; 2021;5.
11.
Nolan  JP , Berg  RA , Andersen  LW ,  et al; Utstein Collaborators.  Cardiac arrest and cardiopulmonary resuscitation outcome reports: update of the Utstein Resuscitation Registry Template for In-Hospital Cardiac Arrest: a consensus report from a task force of the International Liaison Committee on Resuscitation (American Heart Association, European Resuscitation Council, Australian and New Zealand Council on Resuscitation, Heart and Stroke Foundation of Canada, InterAmerican Heart Foundation, Resuscitation Council of Southern Africa, Resuscitation Council of Asia).   Resuscitation. 2019;144:166-177. doi:10.1016/j.resuscitation.2019.08.021PubMedGoogle ScholarCrossref
12.
Jennett  B , Bond  M .  Assessment of outcome after severe brain damage.   Lancet. 1975;1(7905):480-484. doi:10.1016/S0140-6736(75)92830-5PubMedGoogle ScholarCrossref
13.
van Swieten  JC , Koudstaal  PJ , Visser  MC , Schouten  HJ , van Gijn  J .  Interobserver agreement for the assessment of handicap in stroke patients.   Stroke. 1988;19(5):604-607. doi:10.1161/01.STR.19.5.604PubMedGoogle ScholarCrossref
14.
Herdman  M , Gudex  C , Lloyd  A ,  et al.  Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L).   Qual Life Res. 2011;20(10):1727-1736. doi:10.1007/s11136-011-9903-xPubMedGoogle ScholarCrossref
15.
Jensen  CE , Sørensen  SS , Gudex  C , Jensen  MB , Pedersen  KM , Ehlers  LH .  The Danish EQ-5D-5L value set: a hybrid model using cTTO and DCE data.   Appl Health Econ Health Policy. 2021;19(4):579-591. doi:10.1007/s40258-021-00639-3PubMedGoogle ScholarCrossref
16.
Vincent  JL , Moreno  R , Takala  J ,  et al; Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine.  The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure.   Intensive Care Med. 1996;22(7):707-710. doi:10.1007/BF01709751PubMedGoogle ScholarCrossref
17.
Fergusson  D , Aaron  SD , Guyatt  G , Hébert  P .  Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis.   BMJ. 2002;325(7365):652-654. doi:10.1136/bmj.325.7365.652PubMedGoogle ScholarCrossref
18.
Miettinen  O , Nurminen  M .  Comparative analysis of two rates.   Stat Med. 1985;4(2):213-226. doi:10.1002/sim.4780040211PubMedGoogle ScholarCrossref
19.
Fernando  SM , Tran  A , Cheng  W ,  et al.  Pre-arrest and intra-arrest prognostic factors associated with survival after in-hospital cardiac arrest: systematic review and meta-analysis.   BMJ. 2019;367:l6373. doi:10.1136/bmj.l6373PubMedGoogle Scholar
20.
Kahan  BC .  Accounting for centre-effects in multicentre trials with a binary outcome: when, why, and how?   BMC Med Res Methodol. 2014;14:20. doi:10.1186/1471-2288-14-20PubMedGoogle ScholarCrossref
21.
Zou  G .  A modified poisson regression approach to prospective studies with binary data.   Am J Epidemiol. 2004;159(7):702-706. doi:10.1093/aje/kwh090PubMedGoogle ScholarCrossref
22.
Rhodes  A , Evans  LE , Alhazzani  W ,  et al.  Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016.   Crit Care Med. 2017;45(3):486-552. doi:10.1097/CCM.0000000000002255PubMedGoogle ScholarCrossref
23.
Miano  TA , Crouch  MA .  Evolving role of vasopressin in the treatment of cardiac arrest.   Pharmacotherapy. 2006;26(6):828-839. doi:10.1592/phco.26.6.828PubMedGoogle ScholarCrossref
24.
Paradis  NA , Martin  GB , Rivers  EP ,  et al.  Coronary perfusion pressure and the return of spontaneous circulation in human cardiopulmonary resuscitation.   JAMA. 1990;263(8):1106-1113. doi:10.1001/jama.1990.03440080084029PubMedGoogle ScholarCrossref
25.
Mentzelopoulos  SD , Zakynthinos  SG , Siempos  I , Malachias  S , Ulmer  H , Wenzel  V .  Vasopressin for cardiac arrest: meta-analysis of randomized controlled trials.   Resuscitation. 2012;83(1):32-39. doi:10.1016/j.resuscitation.2011.07.015PubMedGoogle ScholarCrossref
26.
Annane  D , Bellissant  E , Bollaert  PE , Briegel  J , Keh  D , Kupfer  Y .  Corticosteroids for treating sepsis.   Cochrane Database Syst Rev. 2015;(12):CD002243.PubMedGoogle Scholar
27.
Lindner  KH , Strohmenger  HU , Ensinger  H , Hetzel  WD , Ahnefeld  FW , Georgieff  M .  Stress hormone response during and after cardiopulmonary resuscitation.   Anesthesiology. 1992;77(4):662-668. doi:10.1097/00000542-199210000-00008PubMedGoogle ScholarCrossref
28.
Smithline  H , Rivers  E , Appleton  T , Nowak  R .  Corticosteroid supplementation during cardiac arrest in rats.   Resuscitation. 1993;25(3):257-264. doi:10.1016/0300-9572(93)90123-8PubMedGoogle ScholarCrossref
29.
Varvarousi  G , Stefaniotou  A , Varvaroussis  D , Xanthos  T .  Glucocorticoids as an emerging pharmacologic agent for cardiopulmonary resuscitation.   Cardiovasc Drugs Ther. 2014;28(5):477-488. doi:10.1007/s10557-014-6547-4PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close